News

TransCure bioServices’ CEO Patrick Nef shares his thoughts on what the changes will mean for drug development In December 2022, the U.S. House of… Read More »The FDA removes animal testing requirement for drug candidates

The immune system plays a powerful role in many pathologies including cancer, inflammatory and autoimmune diseases, but it is not fully understood. To develop… Read More »Everything You Need to Know About Humanized Mouse Models

TransCure bioServices has recently developed new mouse models for studying cancer therapies against Acute myeloid leukemia (AML) in vivo. These mouse leukemia models represent… Read More »What Can We Do For You: New CDX Models for AML Studies

Archamps, December 14th, 2022 – Developed in collaboration with the pharmaceutical industry and academic institutes, BioVolume is the world’s first 3D imaging solution. It… Read More »TransCure bioServices Improves Its Services with 3D Tumor Imaging from Biovolume

Archamps, June 29th, 2022 – Cathay Capital announced its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure… Read More »TransCure bioServices Welcomes Cathay Capital to Accelerate Its Ambitious Growth

TransCure bioServices is proud to announce that our facility is now fully accredited by the AAALAC, a compelling achievement rewarding hard-work and dedication to… Read More »TransCure bioServices is AAALAC Accredited

We all know that 2021 will go into almost everyone’s history book as the vaccine year against the COVID-19 pandemic. It made us realize… Read More »Science VS Sars-Cov-2: Science Could Win

Our initial humanized liver mouse model (hu-PIRF) has now been fully validated in-house thanks to our collaboration with Professor Karl-Dimiter Bissig of Duke University… Read More »TransCure bioServices Launches Humanized Liver Mouse Model